newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment